Mozart Therapeutics Logo Skip to main content
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investment Partners
  • Science
    • Regulatory CD8 T cell network
    • Our Approach
    • Posters and Publications
  • Pipeline
    • Pipeline
    • MTX-101
    • MTX-201
  • News
    • News Releases
  • Careers
    • Job Opportunities
    • Values
    • Benefits
  • Contact

News

MEDIA CONTACT

For media inquiries:
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219

NEWs Releases

October 5, 2026

Mozart Therapeutics Presents Clinical and Preclinical Data Supporting MTX-101 at the 62nd EASD Annual Meeting

April 23, 2026

Mozart Therapeutics Announces Positive Interim Phase 1 Data in Adults with 
Stage 3 Type I Diabetes

May 7, 2025

Mozart Therapeutics Presents Preclinical Data Showing Restoration of CD8 Treg Functionality in Type 1 Diabetes and Early Data from their Targeted IL-15 Program at Immunology 2025™

More news Releases

  • Home
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Investment Partners
  • Science
    • Regulatory CD8 T cell network
    • Our Approach
    • Posters and Publications
  • Pipeline
    • Pipeline
    • MTX-101
    • MTX-201
  • News
    • News Releases
  • Careers
    • Job Opportunities
    • Values
    • Benefits
  • Contact
Logo© 2026 Mozart Therapeutics All rights reservedWebsite Design: Hane Chow, Inc.